COVID-19: advice for chemotherapy and immunotherapy patients

Written by: Dr Mark Tuthill
Published: | Updated: 25/06/2020
Edited by: Laura Burgess

Cancer patients undergoing chemotherapy or immunotherapy during the COVID-19 pandemic may be at higher risk of complications from COVID-19 due to their cancer treatment. The UK government has issued specific advice for patients with cancer and COVID-19 which are regularly updated and should be followed by patients and their medical specialist. Here, medical oncologist Dr Mark Tuthill explains more.

Why are chemotherapy and immunotherapy patients more vulnerable to COVID-19?

Chemotherapy treatments can lower the number of immune cells that are available to fight bacterial and viral infections. The lowering of immune cell counts may make patients who receive chemotherapy for early and advanced cancers with a reduced ability to fight off infections like COVID-19. Once the treatment has completed, your immune counts will recover along with the ability to fight off infections.

For patients on immunotherapy, their immune system is activated and they may potentially develop a stronger immune response against the virus, which may them at higher risk of complications from infection with COVID-19.

If you are worried about your risk you should talk about it with your cancer specialist who will be able to inform you of your individual risk of complication from COVID-19.
 

What precautions should these patients take?

The most important thing for patients to do is follow the current UK government advice with regards to social distancing and shielding for extremely vulnerable patients, which can be found here.

You should discuss the precautions and your risk of infection of COVID-19 with your medical team. They will be able to determine any changes or extra precautions that need to be made to your treatment or social arrangements.
 

Have most chemotherapy treatments stopped?

Although some treatments were paused during the peak of the coronavirus pandemic, most cancer centres in the UK are now going back to offering patients the same or similar treatments for cancer as before the pandemic.

Most doctors in the UK have continued offering treatments that are essential to maintain cancer patient’s health and welling during the pandemic.
 

What alternative treatments might I be offered?

Alternative treatments to chemotherapy are often available and you should discuss these options with your medical team as to determine whether or not they are best for you.
 

What should I do if I show symptoms of COVID-19?

Please ring NHS 111 for advice and follow advice from the UK government website.
 

Can you summarise the situation for cancer patients and COVID-19?

Although patients with cancer that are on chemotherapy and immunotherapy treatments are at higher risk of complication of COVID-19, most patients with cancer or that have had cancer are now able to have usual cancer treatments, provided they and their medical teams follow government advice.

If you have any concerns about your cancer journey, particularly in relation to COVID-19, you should discuss this with your consultant.


If you would like Dr Tuthill to manage your cancer journey, you can book an appointment to see him via his Top Doctor’s profile here.

By Dr Mark Tuthill
Medical oncology

Dr Mark Tuthill is an experienced consultant medical oncologist and an expert in the use of immunotherapy in cancer treatment. Practicing at the Manor Hospital and GenesisCare in Oxford, Dr Tuthill specialises in the treatment of early and recurrent cancer including breast cancer, prostate cancer,kidney cancer, and bladder cancer  Treatment is personalised to each patient's needs and preferences and can include the use of chemotherapy, hormone therapy, immunotherapy, or cancer growth inhibitors.

Dr Tuthill originally qualified from University College London, and trained in Medical Oncology in London at the Royal Marsden, Hammersmith, Charing Cross, and the Chelsea and Westminster Hospitals. In 2015 he was appointed Consultant Medical Oncologist at Churchill Hospital, Oxford, where he acts as principal investigator on a number of clinical trials.

Dr Tuthill’s research interests include tumour immunology, cancer-growth inhibitors, and novel therapeutic drug combinations for the treatment of cancer. He is a principal investigator or sub-investigator for early and late phase clinical trials in tumour types including breast cancer, urological cancers and other tumour types. Dr Tuthill holds a PhD in Tumour Immunology from Imperial College London and regularly presents his research at national and international conferences. He is a clinical ambassador for UCARE (Urology Cancer Research and Education), an independent charity raising funds for research into prostate and bladder cancer, and is a member of The Association of Cancer Physicians.

Dr Tuthill has a medico-legal practice supported by a dedicated a highly professional medico-legal administrative team and medico-legal analysts. He writes clear concise reports to time and client satisfaction.

View Profile

Overall assessment of their patients


This website uses its own and third-party cookies to collect information in order to improve our services, to show you advertising related to your preferences, as well as to analyse your browsing habits..